reflection of its value, and it can be vastly different than the current value of their future cash flows. Progenics (NASDAQ: PGNX ) appears to be a good example of an inefficient market. Last week, 30 days after a positive FDA Advisory Committee meeting
bowel movements during Week 4 of the Treatment Period. Synergy intends to release top-line data from the trial in Q4. Related tickers: ( NKTR -5.2% ) ( AZN -2.1% ) ( CBST -0.8% ) ( SLXP -1.6% ) ( PGNX ) Post your comment!
Gainers: CREG +20% . PGNX +14% . EXEL +12% . KNDI +11% . URS +8% . APP +7% . DGLY +6% . ICPT +5% . Losers: GTAT -6% . Post your comment!
advance illness receiving palliative care when the response to laxatives has been insufficient. Ad Comm briefing docs (NASDAQ: PGNX ) shares are up 12% premarket on robust volume. SLXP premarket activity is unavailable. Post your comment!
However, I rarely write about what happens after an Advisory Committee (Adcom) makes a decision. In the case of Progenics ( PGNX ), I believe that the Adcom has just handed down a significant decision that will help the company (should the FDA adopt it
By Bret Jensen : I have found some of my biggest winners have come from small cap stocks selling for less than $5 a share. These companies receive scant analyst coverage, and one must do the research to uncover hidden gems. I personally look at myriad factors when analyzing the space. Insider ...
Progenics Pharmaceuticals ( PGNX +9.2% ) CEO Mark Baker will comment tomorrow in a conference call on the FDA's Anesthetic and Analgesic Drug Products Ad
the FDA, would potentially mitigate a time-consuming and expensive hurdle for the drug makers in their NDA application efforts. Related tickers: ( CBST -0.6% ) ( NKTR ) ( SLXP +3.2% ) ( THRX -2.4% ) ( PGNX ) Post your comment!
Progenics Pharmaceuticals PGNX announced on March 6 that it would backtrack and reformulate the oral version opioid bowel dysfunction drug MNTX to make it more